
What We're Reading: Anthem Will Not Cover First Drug Approved for Duchenne
What we're reading, October 10, 2016: Anthem will not cover Exondys 51, the first drug approved for treatment of Duchenne muscular dystrophy; big soda has sponsored 96 health and medical groups; and new Illinois program seeks to fill care gaps for working poor.
Citing concerns over the clinical trial data used to approve Sarepta’s treatment for Duchenne muscular dystrophy, Anthem has announced it will not cover Exondys 51.
Coca-Cola Co and PepsiCo have provided sponsorships for nearly 100 health and medical groups combined. A study found that between 2011 and 2015, the 2 soda companies provided 96 sponsorships for groups including the American Heart Association, the American Diabetes Association, and the CDC,
In Illinois, a new program aims to fill care gaps for the working poor. Uninsured residents who earn up to 200% of the Federal Poverty Level are eligible for the new coordinated health program, which will provide an assigned medical home, as well as a primary care physician,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.